ReviewThe journal of allergy and clinical immunology. In practice
Biologics in asthma--the next step toward personalized treatment.
Review in The journal of allergy and clinical immunology. In practice. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 78 citations in OpenAlex.
- Cost-Effectiveness of Biological Asthma Treatments: A Systematic Review and Recommendations for Future Economic Evaluations.PharmacoEconomics · 2018Pooled it
- Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.Drugs · 2026Review
- Trajectories in Oxidative Stress and Corticosteroids Insensitivity in Patient with High Risk of Severe Asthma: Use of FeNO as Biomarker of Respiratory Epithelial Barrier Distress.Life (Basel, Switzerland) · 2026Article
- Psychological and Related Factors Influencing Adherence to Biologic Therapies in Asthma: A Scoping Review.Current allergy and asthma reports · 2025Article
- Impact of a digital web-based asthma platform, a real-life study.BMC pulmonary medicine · 2023Article
- A Better Way to Breathe: Combining Allergy and Pulmonary Care Into One Clinic.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2023Article
- Pharmacometabolomics of Asthma as a Road Map to Precision Medicine.Handbook of experimental pharmacology · 2023Article
- The emerging roles of eosinophils: Implications for the targeted treatment of eosinophilic-associated inflammatory conditions.Current research in immunology · 2022Review
- A review on the effect of COVID-19 in type 2 asthma and its management.International immunopharmacology · 2021Review
- The pharmacoeconomics of the state-of-the-art drug treatments for asthma: a systematic review.Multidisciplinary respiratory medicine · 2021Article
- Guidance for contemporary use of biologics in management of chronic rhinosinusitis with nasal polyps: discussion from a National Institutes of Health-sponsored workshop.International forum of allergy & rhinology · 2020Review
- A comparison of biologicals in the treatment of adults with severe asthma - real-life experiences.Asthma research and practice · 2020Article
- Clinical characteristics of the BREATHE cohort - a real-life study on patients with asthma and COPD.European clinical respiratory journal · 2020Article
- Pediatric asthma: An unmet need for more effective, focused treatments.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2019Review
- How does race and ethnicity effect the precision treatment of asthma?Expert review of precision medicine and drug development · 2019Article
- Still Fighting for Breath: a patient survey of the challenges and impact of severe asthma.ERJ open research · 2018Article
- Eosinophils Target Therapy for Severe Asthma: Critical Points.BioMed research international · 2018Review
- New targets for resolution of airway remodeling in obstructive lung diseases.F1000Research · 2018Review
- Recent advances in biologic therapy of asthma and the role in therapy of chronic rhinosinusitis.F1000Research · 2018Review
- Translational research in pediatric pulmonary disease, 2017.Clinical and translational medicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Asthma is a multifaceted disease and is associated with significant impairment and risk, and a therapeutic response that is highly variable. Although current treatments are usually effective for patients with mild-to-moderate disease, patients with more severe asthma are often unresponsive to current efforts, and there remains a need for agents with properties that may achieve control in these individuals. There is ongoing research to identify bioactive molecules that contribute to the pathophysiology of asthma, and many of these have been identified as potential therapeutic targets to improve control of this disease. As a consequence of these efforts, monoclonal antibodies have been developed and tested as to their effectiveness in the treatment of asthma. The assessment of these new treatments has identified particular pathways that, in selected patients, have shown benefit. The following review will discuss the current and future use of biological agents for the treatment of asthma, their efficacy, and how certain patient phenotypes and endotypes may be associated with biomarkers that may be used to select treatments to achieve greatest effectiveness of their use. As knowledge of the effects of these biological agents in asthma emerges, as well as the patients in whom they are most beneficial, the movement toward personalized treatment will follow.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.